- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00209885
Optimal Multimodal Analgesia in Laparoscopic Cholecystectomy
September 14, 2005 updated by: Hvidovre University Hospital
To test the current standard of care (SOC) treatment for laparoscopic cholecystectomy with a group receiving SOC + additional perioperative analgesics in terms of postoperative abilities, PONV, pain and discharge time from the PACU
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Aim of the study: to compare postoperative complaints (PONV, pain, etc) and PACU discharge time between two groups:
- A: standard of care (SOC)receiving intraoperative dexamethasone, ondansetron, ketorolac, and general anaesthesia with propofol, remifentanil and cisatracurium
- B: SOC + preoperative gabapentin, intraoperative lidocain infusion, s-ketamin and droperidol.
Primary endpoints:
- postoperative abilities over time
- discharge time from PACU according to fixed criteria
- consumption of analgesics and antiemetics in the PACU
Secondary endpoints:
- degree of nursing requirements at the PACU
- General tolerability of the regimes
Study Type
Interventional
Enrollment
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hvidovre
-
Copenhagen, Hvidovre, Denmark, 2650
- Dept of Anaesthesia, Hvidovre Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Elective laparoscopic cholecystectomy
- Age above 18 years
- Written informed consent
- ASA class I-III
Exclusion Criteria:
- Planned abdominal cholecystectomy
- Intraoperative conversion of laparoscopic to laparotomic cholecystectomy
- Allergy to part of the treatment regimens
- Previous reactions to opioids (nausea, cognition)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
1. postoperative abilities over time in PACU
|
|
2. discharge time from PACU according to fixed criteria
|
|
3. consumption of analgesics and antiemetics in the PACU
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
1. Degree of nursing requirements in the PACU
|
|
2. General tolerability of the regimens
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kenneth Jensen, M.D., Dept of Anaesthesia, Acute Pain Service, Hvidovre Hospital, Copenhagen, Denmark
- Study Chair: Claus Lund, dr.med.sci, Dept of Anaesthesia, Hvidovre Hospital, Copenhagen, Denmark
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2005
Study Registration Dates
First Submitted
September 14, 2005
First Submitted That Met QC Criteria
September 14, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
September 21, 2005
Last Update Submitted That Met QC Criteria
September 14, 2005
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathological Conditions, Anatomical
- Gallbladder Diseases
- Biliary Tract Diseases
- Calculi
- Gallstones
- Cholelithiasis
- Cholecystolithiasis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- Anticonvulsants
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Antimanic Agents
- Ketamine
- Lidocaine
- Gabapentin
- Esketamine
- Droperidol
Other Study ID Numbers
- OMA-LC01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.